Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241613 · ClinicalTrials.gov registry record · Phase 1
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Accutar Biotechnology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05241613 is a Phase 1 study that was terminated before completion, run by Accutar Biotechnology. The registered enrollment target is 28 participants.
The verdict
NCT05241613, a Phase 1 study, was terminated before completion, sponsored by Accutar Biotechnology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to participants * Evaluate the side effects of AC176 * Evaluate pharmacokinetics of AC176 * Evaluate the effectiveness of AC176
Interventions
- DRUG AC176
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2024-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05241613
The ClinicalTrials.gov registry entry for NCT05241613 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accutar Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC176 is the first listed.
NCT05241613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05241613 about?
NCT05241613 is a clinical study titled "A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer". This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies. The main goals of this study are to: * Identify the recommended dose of AC176 that can be given safely to...
What is the current status of trial NCT05241613?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-03-16. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT05241613?
The interventions under investigation include: AC176 (DRUG).
Who is sponsoring clinical trial NCT05241613?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.